Business
REDUVO™ - A Major Milestone for Tetra Bio-Pharma Inc.
REDUVO™ - A Major Milestone for Tetra Bio-Pharma Inc..
About this update from Tetra Bio-pharma Inc.
[{"type":"text","content":"\n\n\n\nREDUVO™ - A Major Milestone for Tetra Bio-Pharma Inc.\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nREDUVO™ - A Major Milestone for Tetra Bio-Pharma Inc.\nPR Newswire\nOTTAWA, ON, Oct. 5, 2021\n\n\n\nTetra is gearing up to launch REDUVO™, its first cannabinoid-derived medicine, in Canada. REDUVO™ 5-year cumulative gross sales expected to reach $121M. The Company has started numerous pre-launch activities to prepare for the introduction of REDUVO™ on the Canadian Market. OTTAWA, ON, Oct. 5, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc. (\"Tetra\" or the \"Company\") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today that numerous pre-launch activities for REDUVO™ have been initiated. REDUVO™ is a cannabinoid-derived drug indicated in chemotherapy-induced nausea and vomiting (CINV). In December 2020, the Company submitted a New Drug Submission to Health Canada which is currently in its final stage of review by the regulator.\n\n \n \n \n \n \n \n\n \nThe Company is pleased to share that the following activities have been started or completed:\nDistribution agreement; Reimbursement strategy development; Customer segmentation and targeting; Medical and commercial field team staffing process through a Contract Sales Organization (CSO); and Strategy development and initiation.Steeve Néron, Chief Commercial Officer of Tetra Bio-Pharma said \"We are now entering in a major transformation going from a biotech company strictly focused on research into a biopharma with commercial operations. We remain confident that REDUVO™ shall receive a Notice of Compliance (NoC) from Health Canada in the coming months. REDUVO™ will help us create our Canadian footprint with healthcare professionals to establish our leading position in cannabinoid-derived medicines.\" \nFinancial impacts:\n5-year plan (2022-2026) cumulative gross sales are expected to reach $121M in Canada. REDUVO™ will pave the way for th...